TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00102726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB497115
Description: SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB497115
Description: SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB497115
Description: SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
Study: NCT01411774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (\~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (\~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pill placebo
Description: The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
Study: NCT03792581

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EV1000 and closed-loop system
Description: This system will recommend when patients need fluid or not and adjust vasopressor administration automatically

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EV1000 and closed-loop system
Description: This system will recommend when patients need fluid or not and adjust vasopressor administration automatically
Study: NCT00963547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: \[Part 1\]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. \[Part 2\] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: \[Part 1\]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. \[Part 2\] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
Study: NCT01553942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Daily, Monday-Friday
Study: NCT00885729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cells
Description: Stem cells or chondrocytes under a commercial available membrane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chondrocytes
Description: Implantation of chondrocytes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: Strength exercises, neuromuscular exercises
Study: NCT03665987

Intervention type: BEHAVIORAL
Intervention: consultation in preoperative assessment clinic
Description: The treatment group will be seen in the preoperative clinic before hospitalization, while the control group will get anesthetic consultation after hospitalization without clinic service. No additional interventions will be given during and after surgery.
Study: NCT00963547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
Study: NCT01216306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Television reduction curriculum
Description: Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
Study: NCT04313218

Intervention type: DRUG
Intervention: Carbetocin
Description: iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
Study: NCT03767504

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thymol
Description: Musclin - a dietary supplement: 2 capsules (20 mg thymol per capsule) BID with a meal for 30 days increased to 4 capsules for an additional 30 days.
Study: NCT03962920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline 50 MG
Description: Local instillation of drug directly to the tumour tissue

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local instillation of sterile water directly to the tumour tissue
Study: NCT04980040

Intervention type: DRUG
Intervention: Alogliptin Benzoate
Description: Alogliptin benzoate tablets
Study: NCT01479517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kovacaine Mist 0.1 mL x 4 sprays
Description: Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
Study: NCT01553942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Day 1 of each cycle, IV infusion over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery to remove tumor
Study: NCT02924987

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept Injection
Description: Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
Study: NCT03140267

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Difficult to wean patients
Description: Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
Study: NCT01479517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kovacaine Mist 0.2 mL x 2 sprays
Description: Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kovacaine Mist 0.2 mL x 1 spray
Description: Dose = 1 intranasal spray of study drug
Study: NCT04582162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsplinted implants
Description: Patients received ball abutments on each implant without splinting for retaining an implant retained mandibular overdenture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splinted implants
Description: Patients had their implants splinted using Rhein bars with ball extension for retaining an implant retained mandibular overdenture.
Study: NCT06660641

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % saline
Description: placebo
Study: NCT03445962

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of OSAS predictive factors
Description: All subjects of the two groups realized the same assessment:~* Anthropometric evaluation~* biological examination (hormonal, inflammatory and complete blood count, and lipidic profile)~* rest electrocardiogram~* motor assessment (strenght, flexibility and balance)~* actigraphy~* Autonomic nervous system assessment during sleep~* Autonomic nervous system assessment during head up tilt test before and after physical exercise~* maximal treadmill test (VO2 max measure)~* polysomnography~* seismocardiography~* questionnaires :sleep and physical activity
Study: NCT04481724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gamma-linolenic acid
Description: 3 capsules per day of GLA for 24 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 capsules per day of placebo for 24 months
Study: NCT02038023

Intervention type: DRUG
Group type: OTHER
Intervention: Intravaneous iron(low molecular weight iron dextran)
Description: 1000 mg of Iron dextran administered over one hour
Study: NCT01456247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
Study: NCT04658277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Patients in the intervention arm will take Clarithromycin 250mg daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patients will receive usual medical care
Study: NCT00412659

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for pilonidal disease, midline excision
Description: A midline excision is made for the treatment of pilonidal sinus disease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for pilonidal disease, Karydakis operation
Description: A Karydakis operation is done for the treatment of pilonidal sinus disease.
Study: NCT00585728

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT Virtual Proctoscopy (CTVP)
Description: CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
Study: NCT01206608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKY0402 + bupivacaine HCl
Description: Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mid-dose SKY0402 + bupivacaine HCl
Description: Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
Study: NCT00039832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab (ReoPro) and Reteplase (Retavase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab (ReoPro) and Reteplase (Retavase)
Study: NCT01872988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Administer Tenofovir to HCC patients who are indicated for TACE after randomization
Study: NCT04289324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regular lung recruitment
Description: stepwise oxygenation-guided lung recruitment at regular (twelve hours) intervals during high frequency oscillation ventilation
Study: NCT01159886

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileal intubation
Description: After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.~Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileal intubation
Description: After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.~Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed.
Study: NCT02065635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maintenance with sevoflurane
Description: in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maintenance with propofol
Description: in patients allocated to the propofol group, general anesthesia will be maintained with propofol
Study: NCT05098808

Intervention type: OTHER
Intervention: Acoustic features (from signals obtained during phonation)
Description: Acoustic features will be obtained via phonation files.~A voice recorder application provided by Apple was used, and the sampling frequency of the sound was 44,100 Hz. The digitized cough sound signals were band-pass-filtered between 20 to 16,000 Hz to use data from the whole frequency band gathered by the iPad. In each case, the smart device was positioned 20cm from the patient

Intervention type: OTHER
Intervention: Acoustic features (from signals obtained during phonation)
Description: Acoustic features will be obtained via phonation files.~A voice recorder application provided by Apple was used, and the sampling frequency of the sound was 44,100 Hz. The digitized cough sound signals were band-pass-filtered between 20 to 16,000 Hz to use data from the whole frequency band gathered by the iPad. In each case, the smart device was positioned 20cm from the patient
Study: NCT01849549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: Experimental test about cognitive deficit of interest and standard neuropsychological tests.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neuropsychological testing
Description: Experimental test about cognitive deficit of interest and standard neuropsychological tests.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Anatomical, diffusion, and/or functional MRI

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MRI
Description: Anatomical, diffusion, and/or functional MRI
Study: NCT00911144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)
Description: Intramuscular injection, administered as a single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wyeth-Lederle's Prevenar™
Description: Intramuscular injection, administered as a single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Hiberix™
Description: Intramuscular injection, administered as a single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Hiberix™
Description: Intramuscular injection, administered as a single dose
Study: NCT02378610

Intervention type: OTHER
Intervention: Observation
Description: Observation of the gut bacterial flora in high- and low-stressed individuals

Intervention type: OTHER
Intervention: Observation
Description: Observation of the gut bacterial flora in high- and low-stressed individuals
Study: NCT00002852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study: NCT03170635

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Refreshing Recess program
Description: 6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
Study: NCT02663206

Intervention type: PROCEDURE
Group type: OTHER
Intervention: peroral endoscopic myotomy
Description: peroral endoscopic myotomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Botulinum toxin injection
Description: endoscopic Botulinum toxin (BTX) injection at lower esophagus
Study: NCT02352181

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional coagulation profile Analysis
Description: Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if fibrinogen \<1gram per liter~Platelet concentrate :~* if platelets \<50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.~* if platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :~* if prothrombin\<40% before transfusion at anhepatic phase or in case of bleeding.~* if prothrombin\<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.~Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotem analysis
Description: Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM \<8 mm~Platelet concentrate :~* If MCF EXTEM \<40mm or A10\<35 mm and MCF or A10 FIBTEM \>8mm.~* If platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding.~  2 Fresh frozen plasma if CT EXTEM \>100s.~Bolus Tranexamic acid 1g and 3g every 24 hours :~* if fibrinolysis in EXTEM~* Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes \>15%.~Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.
Study: NCT00065351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013
Description: CC-5013 - oral - 30mg daily on days 1-21 every 28 days
Study: NCT02375529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Incision Laparoscopic Cholecystectomy (SILC)
Description: A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four Ports Laparoscopic Cholecystectomy (4PLC)
Description: An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.~Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation .